Nerve injection under ultrasound for compressed leg nerves in people with diabetes
Tests ultrasound-guided nerve hydrodissection against a sham procedure in people with diabetic leg nerve compression.
Key facts
- Who runs it
- Chongqing Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Ultrasound-Guided Nerve Hydrodissection for Diabetic Lower Limb Entrapment Neuropathy
- Status
- Recruiting
- People taking part
- 266 people, planned
- Started
- 20 May 2026
- Expected to end
- 20 May 2027
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Ultrasound-guided nerve hydrodissection treatment
- Sham treatment
- Record updated
- 17 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with diabetes whose leg nerves are squeezed (entrapment), causing numbness, pain or weakness. Medicines have not helped them enough.
- Age
- 18 to 85 years
- Sex
- Male or female
- Disease stage
- Diabetic nerve damage (DPN) with signs of a squeezed nerve in one or both legs. A doctor's exam must show it. A nerve test or nerve ultrasound must also show it.
- Earlier treatment
- People must have had enough treatment with medicines such as mecobalamin and α-lipoic acid, without enough benefit.
- Biomarker or test result
- Nerve conduction study showing slowed or blocked signals at one site, or nerve ultrasound showing a squeezed nerve.
Main reasons for not taking part
- Another main cause of the leg nerve symptoms, such as spine disease, blood vessel disease, vitamin B12 deficiency, heavy alcohol use or recent chemotherapy
- Cancer, active body-wide infection or immune system disease
- Leg swelling, or broken or infected skin below the knee where treatment is given
- Severe heart, liver or kidney problems (eGFR <30 mL/min/1.73m², liver transaminases >2.5 times the upper limit of normal, or NYHA class ≥II)
- Pregnancy or breastfeeding, memory or thinking problems, or severe mental illness
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age 18-85 years, male or female
- Diagnosis of DLLEN meeting the following criteria: ① Clinical diagnosis of DPN (presence of DPN clinical symptoms plus at least one positive physical sign, or absence of symptoms but presence of two or more positive physical signs), with other etiologies excluded; ② Presence of unilateral or bilateral lower limb symptoms suggestive of peripheral nerve entrapment, including hypoesthesia/paresthesia in a specific nerve distribution area, pain and/or motor dysfunction, or a positive Tinel sign at the corresponding site; ③ Physical examination findings such as decreased or absent skin sensation in the corresponding nerve distribution area, reduced or absent strength of ankle dorsiflexion or eversion, metatarsophalangeal joint movement disorder, foot drop, or foot inversion; ④ Electrophysiological study showing slowing or blockade of nerve conduction velocity at a specific site (across a narrowed segment); ⑤ Imaging study (nerve ultrasound) showing compression of the corresponding nerve (cross-sectional area at the entrapment site exceeding the upper limit of the reference range, decreased nerve echogenicity, or swelling of the nerve fascicles). Diagnosis requires fulfillment of ①, ②, and ③, plus either ④ or ⑤
- Inadequate response to adequate treatment with medications such as mecobalamin and α-lipoic acid
- Understanding of the entire study process and voluntary provision of written informed consent
Who cannot take part
- Concurrent malignancy, active systemic infection, or immune system disease
- Presence of another clearly identified etiology assessed by the investigator as the primary cause of the patient's current lower limb neurological symptoms, including but not limited to: cervical or lumbar spine disease (e.g., radicular symptoms or sciatica), lower extremity vascular disease, cerebral infarction, thyroid dysfunction, vitamin B12 deficiency, heavy alcohol use history, recent chemotherapy or radiotherapy, drug toxicity, or other non-diabetic causes of neuropathy (e.g., CIDP, cauda equina syndrome, subacute combined degeneration of the spinal cord, Guillain-Barré syndrome)
- Skin breakdown or infection at the treatment site below the knee
- Cognitive impairment or severe mental illness
- Any other condition assessed by the investigator as making the patient unsuitable to complete the trial
- Severe cardiac, hepatic, or renal insufficiency (eGFR <30 mL/min/1.73m², liver transaminases >2.5 times the upper limit of normal, or New York Heart Association functional class ≥II)
- Lower limb edema due to any cause
- Pregnancy or breastfeeding
- Participation in another interventional clinical trial within the past 3 months
- Poor compliance, assessed as unlikely to complete the study per protocol
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if a single session of ultrasound-guided nerve hydrodissection can relieve symptoms of diabetic lower limb entrapment neuropathy, a condition caused by compressed nerves in the leg that leads to numbness, pain, or muscle weakness in people with diabetes. The main questions it aims to answer are whether nerve hydrodissection improves nerve function (measured by the Toronto Clinical Scoring System) one month after treatment, and whether it relieves pain and improves quality of life. Researchers will compare two groups: one will receive the actual nerve hydrodissection (injection of medicine around the compressed nerve), and the other will receive a sham procedure that involves injecting a small amount of fluid under the skin (not around the nerve). Participants will not know which group they are in, and the researchers who measure the results will also not know. Participants will have four in-person visits over about one month, complete questionnaires about their nerve symptoms, pain, and quality of life, undergo nerve ultrasound at the beginning and at follow-up visits (at 1 month after treatment), and receive either the nerve hydrodissection or the sham procedure at the second visit. All participants will continue their regular diabetes and nerve medication during the study.
The 2 groups in the trial
- Ultrasound-guided nerve hydrodissection treatment groupTreatment being tested
The patient is placed in a standard position, followed by routine disinfection and draping. A high-frequency ultrasound probe is used and covered with a sterile sheath to clearly visualize the target nerve. Using an in-plane puncture technique, the needle tip is advanced to the perineural fascial plane under real-time guidance. After confirming placement and negative aspiration, a pre-prepared solution of mecobalamin and normal saline is slowly injected. The main sites are the common peroneal nerve (fibular head) and tibial nerve (medial malleolus). Based on preliminary data, a volume of 20 mL is injected, which separates the nerve from surrounding tissues without causing significant discomfort. The fixed volume ensures a standardized procedure. During injection, fluid spread is monitored to ensure it surrounds the nerve and achieves hydrodissection. After injection, the needle is withdrawn, local compression is applied, and the site is covered with a sterile dressing.
Treatment: Ultrasound-guided nerve hydrodissection treatment
- Sham treatment groupSham treatment, for comparison
The patient is placed in the same standard position, followed by identical disinfection and ultrasound positioning. Under ultrasound guidance, a needle identical in appearance is inserted into the superficial subcutaneous fascia above the target nerve, clearly avoiding the nerve structure. A syringe containing mecobalamin and normal saline is then connected, and a full set of simulated injection maneuvers including aspiration and slow "injection" is performed, while ensuring that the actual volume of fluid delivered is small (less than 5 mL). To simulate a real sensory experience, the operator provides standardized verbal cues during the procedure. After needle withdrawal, local compression and dressing application are performed identically to the treatment group.
Treatment: Sham treatment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Ultrasound-Guided Nerve Hydrodissection for Diabetic Lower Limb Entrapment Neuropathy: A Randomized, Single-Blind, Sham-Controlled Trial
- Plain-language title
- Nerve injection under ultrasound for compressed leg nerves in people with diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07625020, who can take part
- Record updated
- 17 June 2026